New Drug Approvals

Home » GENERIC DRUG » TELMISARTAN PART 3/3

TELMISARTAN PART 3/3

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

PAYPAL DONATIONS

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Categories

Blog Stats

  • 1,301,135 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,773 other followers

add to any

Share

 CONT…………………….
PAPER
Journal of Organic Chemistry (2015), 80(3), 1915-1919
J. Org. Chem., 2015, 80 (3), pp 1915–1919
DOI: 10.1021/jo5025333
Abstract Image

A direct and efficient total synthesis has been developed for telmisartan, a widely prescribed treatment for hypertension. This approach brings together two functionalized benzimidazoles using a high-yielding Suzuki reaction that can be catalyzed by either a homogeneous palladium source or graphene-supported palladium nanoparticles. The ability to perform the cross-coupling reaction was facilitated by the regio-controlled preparation of the 2-bromo-1-methylbenzimidazole precursor. This convergent approach provides telmisartan in an overall yield of 72% while circumventing many issues associated with previously reported processes.

Displaying image015.png

Displaying image016.png

Displaying image017.png

Displaying image018.png

Displaying image019.png

……………………

PAPER

International Journal of Research in Pharmaceutical and Biomedical Sciences (2013), 4(1), 293-295

telmisartan1. [Yield 87%, Purity 99.97% by HPLC.M.P. 260 – 262°C, Sulphated ash < 0.01%].

1H NMR (DMSO-d6): δ 0.98-1.03 (t,3H), 1.73- 1.86 (m, 2H), 2.5 – 2.63 (s, 3H), 2.90-2.95 (s, 2H),3.82 (s, 3H), 5.62 (s, 2H), 7.16-7.34 (m,7H), 7.40-7.59 (m,4H), 7.68-7.70 (m, 3H), 12.86 (s, 1H).

M/Z: 515.50 [M + H]+

Displaying image004.png

………………………..

PATENT

WO 2014027280

http://www.google.com/patents/WO2014027280A1?cl=en

Scheme 1 given below:

Formula .

Figure imgf000005_0001

Example 1:

4′-[2-n^ropyl-4-methyl-6-(l-methylbenzimidazol-2-yl)benzimidazol-l-ylmeth^

carboxylic acid

In a 2 litre reaction flask was added 400 ml methylene chloride, followed by 100 gm of 2- cyano-4′ -methyl biphenyl. The reaction mass was stirred to get a clear solution and cooled to 20 °C. Chlorine gas was sparged into the reaction mass for a period of 15 hours till completion of the reaction. The reaction was monitored by TLC using mobile phase n-hexane: ethyl acetate (8:2). The excess chlorine from the reaction mass was removed by flushing with nitrogen. The solvent was distilled out completely by distillation at atmospheric pressure and removal of the final traces under vacuum. To the residual mass, 500 ml of methyl isobutyl ketone was added. The reaction mass was stirred and washed with a solution of 300 ml of 5% sodium bicarbonate solution. The lower aqueous layer was separated and the upper organic layer was washed with 300 ml water. The lower aqueous layer was separated. To the organic layer containing 4-chloromethyl-2′-cyanobiphenyl, the compound 2-n-propyl-4-methyl-6-(l’- methylbenzimidazol-2′-yl)benzimidazole was added, followed by a solution of 40 gm sodium hydroxide in 300 ml water. The reaction mass was stirred for 10 minutes and 10 gm of tetrabutyl ammonium hydrogen sulphate was added. The reaction mass was heated to 80 UC and maintained at 80 to 85 °C for 4 hours.

The completion of the reaction was monitored by TLC using mobile phase chloroform: methanol (9: 1). After completion of reaction, the lower aqueous layer was separated. The solvent was distilled out till mass temperature 120 °C and final traces were removed completely under vacuum. To the residual mass, 50 ml of n-butanol was added and the solvent distilled out under vacuum below 100 °C to remove all traces of methyl isobutyl ketone. The residue was dissolved in 750 ml of n-butanol and 83 gm sodium hydroxide added. The reaction mass was heated to reflux and maintained for 24 hours at 123 to 126 °C. The completion of the reaction was monitored by TLC using mobile phase chloroform: methanol (9: 1). The solvent was distilled out at atmospheric pressure till the mass temperature reached 140 C. The residual mass was cooled to 100 °C and 300 ml water was added. The solvent was distilled out azeotropically till the mass temperature reached 120 °C. To the reaction mass 750 ml of water was added, the solution warmed to 80 °C. The pH of the reaction mass was adjusted to 8.0 with hydrochloric acid. Finally the pH was adjusted to 6.0 with acetic acid, and the reaction mass maintained at 80 to 85 °C for one hour. The product obtained was filtered, washed with water and dried to yield 120 gm of 4′-[2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl)benzimidazol-l-ylmethyl]biphenyl-2-carboxylic acid, which can be purified as per the procedure described mentioned in Example 5. Example 2:

4-chloromethyl-2 ‘-cyanobiphenyl

In a 1 litre reaction flask 400 ml of methylene chloride was added followed by 100 gm of 2- cyano-4′ -methyl biphenyl. The reaction mass was stirred to get a clear solution and cooled to 20 °C. Chlorine gas was sparged into the reaction mass for a period of 15 hours at 20 to 25 °C till completion of the reaction. The reaction was monitored by TLC using mobile phase n- hexane: ethyl acetate (8:2). The excess chlorine from the reaction mass was removed by flushing with nitrogen. The solvent was distilled out completely by distillation at atmospheric pressure and removal of the final traces under vacuum. To the residual mass, 400 ml of n- heptane was added. The reaction mass was stirred and warmed to 60 °C. The clear solution obtained was cooled to 10 °C and the product precipitated was filtered, washed with n-heptane and dried. Further crystallization with n-heptane yielded 80 gm of pure 4-chloromethyl-2’- cyanobiphenyl.

C 73.87%, H 4.41%, N 6.19%; m/z 192.25; 1H NMR DMSO d6400 Mhz : 5ppm 4.84 (s, 2H) 7.32 – 7.66 (aromatic 8H). Example 3:

2-cyano-4,-(2,,-n-propyl-4,,-methyl-6,,-{V”-methylbenzim

ylmethyl) biphenyl

In a 2 litre reaction flask 500 ml of methyl isobutyl ketone was added followed by 100 gm of 2-n-propyl-4-methyl-6-( -methylbenzimidazol-2′-yl)benzimidazole. The reaction mass was stirred and a solution of 40 gm sodium hydroxide in 300 ml water was added. To this solution, 10 gm tetra butyl ammonium hydrogen sulphate and 80 gm of 4-chloromethyl-2′- cyanobiphenyl was added. The reaction mass was warmed to 80 °C and maintained for 4 hours at 80 to 85 °C.

The completion of the reaction was monitored by TLC using mobile phase chloroform : methanol (9:1). After completion of the reaction, the mass was cooled to 20 °C, maintained 3 hours at 15 to 20 °C. The product which precipitated out was filtered, washed with methyl isobutyl ketone, followed by water to yield 126 gm of 2-cyano-4′-(2″-n-propyl-4″-methyl- 6″-(r”-methylbenzimidazol-2″‘-yl)benzimidazol-l”- ylmethyl) biphenyl, melting at 196 – 198 °C. C 80.53%, H 5.70%, N 14.20%; m/z = 496.64 lH NMR DMSO d6 400 Mhz : 5ppm 0.96 – 0.99 (t, 3H) 1.75 – 1.84 (m, 2H) 2.62 (s, 3H) 2.89 – 2.93 (t, 2H) 3.80 (s, 3H) 5.67 (s, 2H) 7.18 – 7.92 (m, 14H)

Example 4:

4′-[2-n^ropyl-4-methyl-6-(l-methylbenzi idazol-2-yl)benzi idazol-ylmethyl]bipheny carboxylic acid

126 gm of 2-cyano-4′-(2″-n-propyl-4″-methyl-6″-(l “‘-methylbenzimidazol-2″‘-yl) benzimidazol-1”- ylmethyl) biphenyl was dissolved in 750 ml of n-butanol and 83 gm sodium hydroxide added. The reaction mass was heated to reflux and maintained for 15 hours at 123 to 126 °C. The completion of the reaction was monitored by TLC using mobile phase chloroform: methanol (9: 1).

The solvent was distilled out at atmospheric pressure till the mass temperature reached 140 °C. The residual mass was cooled to 100 °C and 300 ml water was added. The solvent was distilled out azeotropically till the mass temperature reached 120 °C. To the reaction mass 750 ml of water was added, the solution warmed to 80 °C. The pH of the reaction mass was adjusted to 8.0 with hydrochloric acid. Finally the pH was adjusted to 6.0 with acetic acid, and the reaction mass maintained at 80 to 85 °C for one hour. The product obtained was filtered, washed with water and dried to yield 120 gm of 4’-[2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl)benzimidazol-l-ylmethyl]biphenyl-2-carboxylic acid. Example 5:

Purification of 4′-[2-n^ropyl-4-methyl-6-(l-methylbenzimidazol-2-yl)benzimidazol-l- ylmethyl]biphenyl-2-carboxytic acid

In a 3 litre reaction flask, 1000 ml of methanol was added followed by the addition of 120 gm of 4′-[2-n-propyl-4-methyl-6-(l-methylbenzimidazol-2-yl)benzimidazol-l-ylmethyl]biphenyl- 2-carboxylic acid obtained by procedure described in Example 4. The solution was warmed to 50 °C and pH adjusted to 10.0 to 10.5 with 100 ml of a 10% methanolic potassium hydroxide solution. The reaction mass became a clear solution, and 6 gm activated carbon was added. The mass was maintained at 50 to 55 °C for one hour and filtered through hyflo supercel to remove the activated carbon. The clear filtrate obtained was collected and its pH adjusted to 6.0 to 6.5 with 130 ml of acetic acid, maintaining the temperature between 50 to 55 °C. The mass was cooled to 15 °C and maintained one hour at 10 to 15 °C. The product which precipitated out was filtered, washed with 50 ml of methanol followed by 500 ml of water. The wet product was dried to yield 107 gm of 4′-[2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl)benzimidazol-l-ylmethyl]biphenyl-2-carboxylic acid.

C 76.49%; H 5.74%, N 11.02%; m/z 515.45.; 1H NMR DMSO d6 400 Mhz : 5ppm 0.97 – 1.01 (t, 3H) 1.76 – 1.85 (m, 2H) 2.62 (s, 3H) 2.90 – 2.94 (t, 3H) 3.81 (s, 3H) 5.61 (s, 2H) 7.15 – 7.71 (14H aromatic);

Melting point of purified telmisartan: 269 °C.

…………………

PAPER

Journal of Organic Chemistry (2014), 79(21), 10568-10580

http://pubs.acs.org/doi/abs/10.1021/jo501665e

J. Org. Chem., 2014, 79 (21), pp 10568–10580
DOI: 10.1021/jo501665e
Abstract Image

On the basis of our recently reported aniline aqueous borylation, molecular diversity was achieved in a one-pot process by combining other reactions such as esterification, Suzuki–Miyaura coupling, hydrogenolysis, or Petasis borono-Mannich.

TELMISARTAN IS COMPD 9

……………….

PATENT

US 20150031768

(EN)

Methods of halogenating a carbon containing compound having an sp3 C—H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by nucleophilic substitution with F are provided. Methods of direct oxidative C—H fluorination of a carbon containing compound having an sp3 C—H bond are provided. The halogenated products of the methods are provided.

…………………..

PATENT

WO 2014067237

http://www.google.com/patents/WO2014067237A1?cl=en

Telmisartan Preparation: 12 Examples

The title compound (III, R = COOCH 3) (52.8g, O. lmol) of Example 11 with glacial acetic acid

(200ml) and concentrated hydrochloric acid (250ml) mixing, 100 ° C to react for 5 to 6 hours. Evaporated to most mixed acid, residue slowly poured into crushed ice, under ice cooling with saturated K 2 CO ^ solution to adjust the pH to neutral, solid precipitation, filtration, filtrate was washed with water, was for Mischa Tan crude, recrystallization telmisartan (40.1g), liquid purity greater than 99%.

Example 13: Preparation of telmisartan of formula I compound (0.62g, leq) was added to acetonitrile (10ml). After stirring evenly, the KOH (0.14g, 1. leq) was slowly added, after stirring for 10 plus minutes, the title compound of Example 10 of the embodiment (11, R = COOCH 3) (0.5g, leq) was slowly added, stirred for 3-4 hours, TLC the reaction was complete, the direct addition of 50% ethanol (30mL), reflux The reaction for 6 hours. After completion of the reaction by TLC, recovering the organic solvent under reduced pressure, the remaining solution was added dropwise hydrochloric acid (1: 1) to neutral pH. The precipitated solid was filtered, washed with water to give crude telmisartan, telmisartan recrystallized (yield 75.1%), the liquid phase is greater than 98% purity.

Chloromethyl biphenyl -2- (II, R = CN) Preparation of 4′-nitrile:

…………………

Journal of Pharmaceutical and Biomedical Analysis (2015), 108, 86-96.

………………..

IN 262831/EP 1912975

……………………….

JP 2014201585

……………………..

 IN 2013KO00463/WO 2014174397

…………………………….

PATENT

http://www.google.com/patents/CN1768044A?cl=en

Example 7: Telmisartan make 5.51 g telmisartan × HCl was dissolved in 50 ml of 40% acetic acid while refluxing. The brown solution was then filtered hot through 1.1 g of carbon, 2.5 ml of 40% acetic acid and washed, and at 80-90 ℃ 2.5 ml of 4N NaOH was added dropwise with stirring to light brown filtrate. Telmisartan crystallization, the suspension was diluted with 30 ml of water, and slowly cooled to ambient temperature. Telmisartan suction filtration, and washed with 50 ml of water. And dried in vacuo at 80 ℃ drying cabinet telmisartan.

Yield: 4.80 g (93.3% of the theoretical yield).

……………………………….

PATENT

http://www.google.com/patents/CN102731407A?cl=en

Figure CN102731407AD00041

Figure CN102731407AD00042

Example 4 Preparation of telmisartan

[0031] 2-n-propyl group as shown in Formula I-4-methyl-6- (benzimidazol-2-yl-methyl 1’_) benzimidazole (30. 4g, O. 10mol), 4_ bromomethyl-biphenyl-2-carboxylic acid (43. 6g, O. 15mol), three ko amine (12. Ig, O. 15mol) and ko ni ni ether 500ml alcohol were mixed and reacted at 100 ° C for 6 inches The reaction solution was poured into ice water, acidified with dilute hydrochloric acid and slowly adjusted PH2-3, to precipitate a solid. Filtration, 70 ° C drying crude, the resulting crude product ko ko acid ester 300ml heating beating again. Filtered, 70 ° C dry. Recrystallization from DMF telmisartan of formula III as shown in 25. Ig, yield: 50%.

…………………….

PATENT

http://www.google.com/patents/WO2010146187A2?cl=en

For example, WO 2004/087676 describes the hydrolysis of a compound with the chemical name 4 ‘-((1,7’- dimethyl-2 ‘ -propyl-lH, 3 ‘H-2, 5 ‘ -bibenzo [d] imidazol-3 ‘ -yl) – methyl) biphenyl-2-carbonitrile and having formula 2

Figure imgf000004_0001

which is hereinafter referred to as cyanotelmisartan . In par- ticular, the hydrolysis of cyanotelmisartan is carried out at elevated temperatures using strong alkaline conditions. Also, CN 1412183 discloses the hydrolysis of cyanotelmisartan.

US 2006/0264491 Al discloses the hydrolysis of 4′-((l,7′- dimethyl-2 ‘ -propyl-lH, 3 ‘H-2, 5 ‘ -bibenzo [d] imidazol-3 ‘ – yl) methyl) biphenyl-2-carboxamide having formula 3

Figure imgf000004_0002

Example 2: Preparation and isolation of telmisartan

Into a reaction vessel 20.5g (40 mmol) 4 ‘ – ( (1, 7 ‘ -dimethyl-2 ‘ – propyl-IH, 3 ‘ H-2 , 5 ‘ -bibenzo [d] imidazol-3 ‘ -yl) methyl) biphenyl-2- carboxamide and 20 ml (lδOmmol) H2SO4 (1:1) were added. The re- action mixture was heated to about 125°C and stirred at this temperature for 28 h. A sample of the reaction mixture was analyzed by Area% HPLC (starting compound below 0.1%, telmis- artan over 97%) . The reaction mixture was cooled below 800C and 250 ml of water were added. Then, 200 ml of dichloro- methane were added and pH value of mixture was adjusted to 5.4 by addition of 6M NaOH. The mixture was stirred for approximately 5 min and then the phases were separated. The water phase was reextracted by 136 ml of dichloromethane . Collected organic phases were washed with water (2χl36ml) and then treated with activated charcoal (5.3 g) . Subsequently, the organic phase was evaporated an oily residue (26g) . 264 ml of acetone were added. The mixture was stirred at room temperature for at least 6 hours. The precipitated product was sepa- rated and washed with fresh acetone and dried at 65°C under reduced pressure for 3 hours. Yield: 18.3g (89%) Area % HPLC: Telmisartan 99.80%

Example 3: Isolation of telmisartan

Into a reaction vessel 7.5g (15 mmol) of cyanotelmisartan, 30 ml of propylene glycol, 0.8 ml of water and 3g (45 mmol) of 85% KOH were added. The reaction mixture was heated to around 1600C to 170 0C and stirred at this temperature for 24 h. The reaction mixture was cooled below 800C and 75 ml of water were added. Then, pH value of the mixture was adjusted to 4.8 (by addition of 6M HCl) and then 150 ml of dichloromethane were added. The mixture was stirred for approximately 5 min and then the phases were separated. The water phase is reextracted by 50 ml of dichloromethane. Collected organic phases were washed with water (2χ50ml) and then treated with activated charcoal (2 g) . After that the organic phase was evaporated to an oily residue (9.8g) . 100 ml of acetone were added. The mix- ture was stirred at room temperature for at least 6 hours. The precipitated product was separated and washed with fresh acetone and dried at 65°C under reduced pressure for 3 hours. Yield: 6.8g (88%) Area % HPLC: Telmisartan 99.60%

 

 

…………………….

PATENT

http://www.google.com/patents/CN1548421A?cl=en

Specific embodiments

14 ‘Example – [(1,4′-dimethyl-2′-propyl [2,6′- two-1H – benzoimidazol] 1′-yl) methyl] – [1, 1’-biphenyl] -2-carboxylic acid sodium salt in 250ml reaction flask, telmisartan 10g (0.0195mol), NaOH0.75g (0.0189mol) and water 100ml, stirred for 1 hour (30 ℃), filtered insoluble materials are removed and concentrated to a small volume, plus ethanol 30ml, concentrated, washed with 30ml of n-hexane, decanted, plus ethanol 30ml, concentrated, and then repeat again, and concentrated to dryness to obtain telmisartan sodium salt 9.9g yield 95.2%. Melting point: 223-225 ℃.

Elemental analysis: C33H29N4O2Na · H2O Calcd: C71.48 H5.10 N10.11 Found: C71.42 H5.08 N10.22 Example 24 ‘- [(1,4′-dimethyl-2′-n propyl [2,6′- two-1H – benzoimidazol] 1′-yl) methyl] – [1,1’-biphenyl] -2-carboxylic acid potassium salt in 250ml reaction flask, Telmisartan 10g (0.0195mol), KOH1.06g (0.0188mol) and water 100ml, stirred for 1 hour (30 ℃), filtered to remove insolubles, and concentrated to a small volume, ethanol 30ml, concentrated, hexane 30ml washed, decanted, plus ethanol 30ml, concentrated, and then repeat again, and concentrated to dryness to obtain telmisartan potassium 10.6g, yield 95.6%. Melting point: 203-205 ℃.

Elemental analysis: C33H29N4O2K · H2O Calcd: C69.04 H5.40 N9.76 Found: C69.01 H5.28 N9.88 Example 3 starting material and the mixed powder was sieved excipients, 5% polyethylene pyrrolidone was granulated and dried. After dried particles were sieved magnesium stearate was added mixed tabletted.

mg / tablet of telmisartan sodium salt 20 Lactose 170 Sodium carboxymethyl starch 10 mg Magnesium stearate 8 meglumine 25% polyvinyl pyrrolidone solution q.s. Example 4 A mixed powder of raw materials and auxiliary materials sieved, added 5 % solution of polyvinylpyrrolidone is granulated and dried. After dried particles were sieved magnesium stearate was added mixed tabletted.

mg / tablet telmisartan sodium Lactose 200 40 140 DCP sodium carboxymethyl starch 16 mg Magnesium stearate 45% povidone solution appropriate amount of Example 5 of this product, according to the dissolution assay (Chinese Pharmacopoeia 2000 edition Appendix II XC second method), phosphate buffer 900ml solvent, the speed of 75 revolutions per minute, operate according to the law, after 30 minutes, take the solution as spectrophotometry (Chinese Pharmacopoeia 2000 edition of the test solution, according to the spectrophotometric two Appendix IVA), absorbance was measured at 295nm wavelength. Another reference standard stock solution 10ml precise amount of determination under set 100ml flask, diluted with phosphate buffer to the mark, then the precise amount of 5ml, set 10ml volumetric flask, dilute to the mark with phosphate buffer , shake, the same method absorption, calculated for each piece of the dissolution of the limits of 80% scalar, should be specified. Dissolution test results in Table.

Table dissolution test results Dissolution (%) telmisartan sodium 97.29 99.65 102.55 95.83 101.10 98.92 99.20 ± 2.45

…………………..

PATENT

http://www.google.com/patents/CN1412183A?cl=en

Example 5 4 ‘- [(1,4′-dimethyl-2′-propyl [2,6′- two -1H- benzimidazol] -1′-yl) methyl] – [1,1’ – biphenyl] -2-carboxylic acid (III) IV (24.8g, 0.05mol) was added ethylene glycol (100ml) and water (150ml) (or other previously described a mixed solvent), sodium ethoxide (or as previously said other alcohols sodium) (13.6g, 0.2mol), was refluxed for 10 hours. After no starting material by TLC was cooled to room temperature, hydrochloric acid was added dropwise (1/1) to pH 5-6, the precipitated solid was filtered, washed with water to give III.

……………………

PATENT

http://www.google.com/patents/CN101550107B?cl=en

Example 3

[0047] 1) Preparation of telmisartan crude methyl ester

Compound II into 50g in 500mL reaction flask, 200mL of methyl isobutyl ketone (MIBK), 25 ° C _30 ° C with stirring until dissolved, was added dropwise 35mL of triethylamine was added 55. Og After the completion of the compound III, 5 (T60 ° C or so for about 4_5 hours, TLC monitoring completion of the reaction, filtered and the filter cake washed with a small amount of MIBK, and then washed with water, dried to give 70. 3g of crude product. 81% yield, purity of about 98%.

(TLC test conditions: ethyl acetate: methanol = 8: 1)

 2) preparation of high purity methyl telmisartan

 IOOOmL reaction flask, the input step to give the crude methyl ester telmisartan, add 500mL of isopropanol was heated to dissolve, 2gX 2 activated bleaching filtrate was heated to about 90 ° C, added dropwise with stirring 150mL 7jC insulation 0. 5~Ih, cooled slowly to room temperature with stirring. Filtered, and the filter cake washed sequentially with MIBK and water washing, and drying, the yield of about 82%, HPLC purity 99.5%, the single impurities less than 0.1%.

3) Preparation of telmisartan with high purity

[0053] A reaction flask was put in a 500mL high purity 15g telmisartan ester, 3. Og sodium, 200mL of isopropanol, water, 80ml, was heated to reflux for 5 ~ 7 h, TLC monitoring of the reaction was complete, the distillation Isopropanol was removed, and water was added to completely dissolve the solid 40ml, 0. 5g of activated carbon bleaching, the filtrate was added 50ml of water, heated to 80 ° C, lmol / L of acetic acid to adjust the pH to 5. (Γ5. 5, filtered, and the filter cake dried to give 13. 14g of solid, yield 90%, HPLC purity 99.7%, the single impurities less than 0.1%.

(TLC test conditions: ethyl acetate: methanol = 8: 1)

………………………..

http://www.google.com/patents/CN101172968B?cl=en

Example 1

[0023] 1, 100gPPA, 21. 8g (0. Lmol) 2_ n-propyl _4_ _6_ carboxyl methyl benzimidazole and 21. 5gN- methyl-o-phenylenediamine added to the reaction flask in under N2 protection feeding, heated to IO (TC _1601 :, reaction 8-20 hours, down 70-80.C 200ml water was added and the reaction with hydrochloric acid to adjust ffl = 1~2, put charcoal 5_8%,, 8 (TC about 5 to 10 minutes, filtered, and the reaction repeated, the adjustment ra 12-14 with NaOH, for several hours, and filtered to give the crude intermediate 2-n-propyl -4-methyl-6- (benzimidazol-2-yl-methyl ) benzimidazole sodium salt. [0024] 2, the product of the previous step, 2-n-propyl -4-methyl–6_ (methyl benzimidazol-_2_ yl) benzimidazole sodium salt crude product was dissolved into 200 ml of ethanol , and dissolved by heating, cooling to room temperature, 400 ml 1N NaOH, to precipitate the compound 2-n-propyl -4-methyl-6- (methyl benzimidazol-2-yl) benzimidazole .50-8 ( TC dried in vacuo. [0025] 3, product of the previous step -4-methyl-2-n-propyl -6_ (methyl benzimidazol-_2_ yl) benzimidazole into 200 ml of dimethyl sulfoxide was stirred was added at room temperature and 4-bromomethyl – biphenyl-2-carboxylic acid methyl ester 33.55 g, was stirred for 14 hours, extracted with dichloromethane (200, 100, 100), and evaporated to dryness under reduced pressure, 300 ml of methanol and 10% potassium hydroxide (240 ml, 0. 6mo1) mixture was refluxed for 6 hours, cooled, washed with 80 ml of methylene chloride, adjusted with glacial acetic acid ffl = 6, a lot of white floc precipitated precipitate was filtered and dried to give a white Tilmicosin 49.6 g of crude product, the crude product was added 100 ml of chloroform was heated to reflux, activated carbon decolorization, crystallization, filtration, 8 (TC dried in vacuo to give a white pure telmisartan (HLPC> 99. 0%) 41 克, purification yield 82%. mp 261~263.C, H-NMR (d6-DMS0) S 1. 05t, 3H), 1. 83 (m, 2H), 2. 71 (s, 3H), 2. 94 (t, 2H), 3. 81 (s, 3H), 5. 57 (s, 2H), 7. 16-7. 83 (m, 14H) • C33H33N402 [0026] Example 2 Preparation of telmisartan

 1, 100gPPA, 21. 8g (0. 1) 2_ [4-methyl-n-propyl-benzimidazole and _6_ 21. 5gN- carboxy-o-phenylenediamine added to the reaction flask in N2 Under the protection of feeding, heated to 100 ° C _160 ° C, the reaction for 8-20 hours, down 70-80. C, the reaction was added 200ml of water, adjusted with hydrochloric acid ffl = 1~2, into charcoal 5_8%, about 8 (TC 5_10 minutes filtered again reacted with K0H ra adjusted to 12-14 for several hours and filtered to give Intermediate crude 2-n-propyl -4-methyl-6- (benzimidazol-2-yl-methyl) benzimidazole potassium salt.

 2, the product of the previous step, 2-n-propyl -4-methyl–6_ (methyl benzimidazol-_2_ yl) benzimidazole potassium salt of the crude product into 200 ml of ethanol, and dissolved by heating, cooling to room temperature was added 400 ml 1N K0H, a precipitated compound is 2-n-propyl -4-methyl-6- (benzimidazol-2-yl-methyl) benzimidazole potassium salt. 50-8 (TC dried in vacuo. [0029] 3, 2-n-propyl prepared in the previous step -4-methyl-6- (benzimidazol-2-yl-methyl) benzimidazole potassium salt and 27.2 g of 4-bromomethyl-2-cyanobiphenyl, 10.4 g of triethylamine and DMF (DMA, dichloromethane, dichloroethane) were mixed and reacted for 5-10 hours at 35-40 °, TLC detection After no starting material the reaction mixture was poured into 600 g of ice water, extracted with ethyl acetate (300ml * 3), the combined organic phases were washed with water (300ml * 2), dried and desolvation, and then petroleum ether was added and stirred until a solid precipitated was The crude product was 45.6 g.

4, the upper step of the solid 45.6 grams, was added 200ml of ethylene glycol, 150ml water, 12 g of sodium hydroxide, the reaction was refluxed for 10 hours, TLC detected no starting material and then cooled to room temperature, acidified with hydrochloric ra is 5 to 6, there is solid precipitation, filtration, washing, telmisartan was crude, DMF and recrystallized to give 44.5 g of telmisartan pure product (HLPC> 99. 0%) mp261~263 ° C. Force -NMR (de-DMS0) S 1. 05t, 3H), 1. 83 (m, 2H), 2. 71 (s, 3H), 2. 94 (t, 2H), 3. 81 (s, 3H ), 5. 57 (s, 2H), 7. 16-7. 83 (m, 14H) • C33H33N402 [0031]

……………………….

Citing Patent Filing date Publication date Applicant Title
CN100460396C Mar 8, 2007 Feb 11, 2009 杭州盛美医药科技开发有限公司 Intermediate of telmisartan, preparation and use thereof
CN100506799C Apr 19, 2007 Jul 1, 2009 北京理工大学 [(2-n-propyl-4-methyl-1H-Benzimidazole)6-radical] carboxamide-1-radical] methylbiphenyl compound, synthesizing method and usage
CN100548293C Aug 8, 2003 Oct 14, 2009 贝塞斯达药物股份有限公司 Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure
CN101550107B Apr 2, 2009 Jan 12, 2011 宁波九胜创新医药科技有限公司 Method for preparing telmisartan
CN101743228B Jul 3, 2008 Jan 29, 2014 新梅斯托克尔卡托瓦纳兹德拉韦尔公司 Process for preparing telmisartan
CN101891735B Nov 25, 2009 Jul 18, 2012 北京理工大学 Biphenyl sulfafurazole compound, synthesis method and application thereof
CN102093297B Jan 28, 2011 Aug 1, 2012 海南美兰史克制药有限公司 Telmisartan compound and new preparation method thereof
EP1805146A2 * Oct 18, 2005 Jul 11, 2007 Dr. Reddy’s Laboratories Ltd. Process for preparing telmisartan
EP2123648A1 May 20, 2008 Nov 25, 2009 Chemo Ibérica, S.A. A process for the preparation of Telmisartan.
US7501448 Oct 13, 2005 Mar 10, 2009 Teva Pharmaceutical Industries, Ltd. high yields, low cost process; easy solvent extraction; nontoxic, safe, environmentally friendly, low boiling point organic solvents; 1,7′-dimethyl-2′-propyl-1H,3’H-[2,5′]bibenzoimidazolyl is reacted with 4’bromomethyl-biphenyl-2-carboxylic acid alkyl ester; industrial scale; hydrolysis
US8691999 * May 10, 2005 Apr 8, 2014 Cipla Limited Process for the preparation of telmisartan
WO2006044648A1 * Oct 13, 2005 Apr 27, 2006 Teva Pharma Process for preparing telmisartan
WO2007010558A1 * Jul 19, 2006 Jan 25, 2007 Satyanarayana Chava A process for the preparation of telmisartan
WO2009123483A1 Mar 30, 2009 Oct 8, 2009 Zaklady Farmaceutyczne Polpharma Sa Process for preparation of telmisartan
WO2012028925A2 Aug 29, 2011 Mar 8, 2012 Ogene Systems (I) Pvt Ltd An improved process for the preparation of telmisartan
CN1412183A Oct 15, 2001 Apr 23, 2003 中国科学院上海药物研究所 New preparation method of timixatan
CN1620437A Jan 15, 2003 May 25, 2005 贝林格尔英格海姆法玛两合公司 Method for the production and purification of 1, 7′-dimethyl-2′-propyl-2, 5′-bi-1h-benzimidazole
CN1768044A Mar 26, 2004 May 3, 2006 贝林格尔·英格海姆国际有限公司 Process for manufacture of telmisartan
WO2005108375A1 May 10, 2005 Nov 17, 2005 Cipla Ltd Process for the preparation of telmisartan
CN1344712A Jul 30, 2001 Apr 17, 2002 中国科学院上海药物研究所 Synthesis path of Timisatem
CN1412183A Oct 15, 2001 Apr 23, 2003 中国科学院上海药物研究所 New preparation method of timixatan
US2006/0094883 Title not available
WO03/059890A1 Title not available
WO2005/108375A1 Title not available
US7501448 Oct 13, 2005 Mar 10, 2009 Teva Pharmaceutical Industries, Ltd. high yields, low cost process; easy solvent extraction; nontoxic, safe, environmentally friendly, low boiling point organic solvents; 1,7′-dimethyl-2′-propyl-1H,3’H-[2,5′]bibenzoimidazolyl is reacted with 4’bromomethyl-biphenyl-2-carboxylic acid alkyl ester; industrial scale; hydrolysis
WO2007147889A2 * Jun 22, 2007 Dec 27, 2007 Krka Tovarna Zdravil D D Novo Preparation of telmisartan salts
WO2010146187A2 Jun 21, 2010 Dec 23, 2010 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2012055941A1 Oct 26, 2011 May 3, 2012 Krka,Tovarna Zdravil, D. D., Novo Mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
WO2003007876A2 Jun 25, 2002 Jan 30, 2003 Sumner H Burstein N-fatty acid-amino acid conjugates and therapeutic uses
WO2003059327A1 Jan 16, 2002 Jul 24, 2003 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
WO2004028505A1 Sep 18, 2003 Apr 8, 2004 Boehringer Ingelheim Int Solid pharmaceutical formulations comprising telmisartan
WO2004087676A1 Mar 26, 2004 Oct 14, 2004 Boehringer Ingelheim Int Method for the production of telmisartan
WO2004096215A1 Apr 27, 2004 Nov 11, 2004 Boehringer Ingelheim Int Pharmaceutical formulation of the sodium salt of telmisartan
WO2005108375A1 * May 10, 2005 Nov 17, 2005 Cipla Ltd Process for the preparation of telmisartan
WO2006044754A2 Oct 18, 2005 Apr 27, 2006 Muthulingam Arunagiri Process for preparing telmisartan
WO2006050509A2 Nov 3, 2005 May 11, 2006 Teva Pharma Amorphous and polymorphic forms of telmisartan sodium
WO2006050921A2 Nov 9, 2005 May 18, 2006 Lek Pharmaceuticals Preparation of telmisartan salts with improved solubility
WO2006063737A1 Dec 9, 2005 Jun 22, 2006 Boehringer Ingelheim Int Combination therapy comprising telmisartan and hydrochlorothiazide
WO2006136916A2 Jun 20, 2006 Dec 28, 2006 Glenmark Pharmaceuticals Ltd Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
WO2007010559A2 Jul 19, 2006 Jan 25, 2007 Panacea Biotec Ltd Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
WO2007060170A2 Nov 22, 2006 May 31, 2007 Boehringer Ingelheim Int Bilayer tablet comprising telmisartan and diuretic
WO2007144175A2 Jun 14, 2007 Dec 21, 2007 Lek Pharmaceuticals Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
WO2007147889A2 Jun 22, 2007 Dec 27, 2007 Krka Tovarna Zdravil D D Novo Preparation of telmisartan salts
WO2009004064A1 Jul 3, 2008 Jan 8, 2009 Krka Tovarna Zdravil D D Novo Process for preparing telmisartan
CN1412183A Oct 15, 2001 Apr 23, 2003 中国科学院上海药物研究所 New preparation method of timixatan
CN1548421A May 22, 2003 Nov 24, 2004 上海医药工业研究院 Tilmisartan salt and its prepn
EP0502314A1 Jan 31, 1992 Sep 9, 1992 Dr. Karl Thomae GmbH Benzimidazol, medicaments containing them and process for their preparation
EP1144386A1 Jan 7, 2000 Oct 17, 2001 Boehringer Ingelheim Pharma KG Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
EP1719766A2 Apr 18, 2006 Nov 8, 2006 Dipharma S.p.A. A process for the preparation of telmisartan
US20060264491 Jun 8, 2006 Nov 23, 2006 Chemagis Ltd. Telmisartan production process
CN101172968B Nov 1, 2006 May 12, 2010 浙江天宇药业有限公司 2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same
CN101743228B Jul 3, 2008 Jan 29, 2014 新梅斯托克尔卡托瓦纳兹德拉韦尔公司 Process for preparing telmisartan
CN102015690B Mar 19, 2009 Apr 30, 2014 力奇制药公司 Catalyzed carbonylation in the synthesis of angiotensin II antagonists
CN102036937B Mar 19, 2009 Jun 4, 2014 力奇制药公司 2′-halobiphenyl-4-yl intermediates in the synthesis of angiotensin ii antagonists
WO2014067237A1 * Oct 31, 2013 May 8, 2014 Topharman Shanghai Co., Ltd. Telmisartan preparation method and intermediate thereof
WO2010018441A2 * Aug 10, 2009 Feb 18, 2010 Cadila Pharmaceuticals Ltd. An improved process for the preparation of substantially pure telmisartan
WO2010146187A2 * Jun 21, 2010 Dec 23, 2010 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011077444A1 * May 28, 2010 Jun 30, 2011 Inogent Laboratories Private Limited A new process for the preparation of pure telmisartan
WO2012028925A2 * Aug 29, 2011 Mar 8, 2012 Ogene Systems (I) Pvt Ltd An improved process for the preparation of telmisartan
CN1768044A * Mar 26, 2004 May 3, 2006 贝林格尔·英格海姆国际有限公司 Process for manufacture of telmisartan
CN102731407A * Jul 4, 2012 Oct 17, 2012 宁波九胜创新医药科技有限公司 Method for preparing telmisartan
EP0627433A1 * Dec 7, 1993 Dec 7, 1994 Eisai Co., Ltd. Process for producing imidazopyridine derivative and intermediate
EP2123648A1 * May 20, 2008 Nov 25, 2009 Chemo Ibérica, S.A. A process for the preparation of Telmisartan.
EP2305650A1 * Sep 21, 2009 Apr 6, 2011 Chemo Ibérica, S.A. Novel process for the preparation of telmisartan
KR20090000113A * Title not available
US20040236113 Mar 17, 2004 Nov 25, 2004 Boehringer Ingelheim International Gmbh Process for manufacture of telmisartan
US20130137878 Jan 25, 2013 May 30, 2013 Boehringer Ingelheim International Gmbh Process for manufacture of telmisartan

……..

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.




COCK WILL TEACH YOU NMR

COCK SAYS MOM CAN TEACH YOU NMR

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO …..FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK

Join me on twitterFollow amcrasto on Twitter

Join me on google plus Googleplus

 

 amcrasto@gmail.com


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Paypal Donate

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,773 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 29 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 29 year tenure till date Aug 2016, Around 30 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 25 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 13 lakh plus views on New Drug Approvals Blog in 212 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →

TWITTER

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: